Just like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

Background: Twin anemia–polycythemia sequence (TAPS) is a rare monochorionic complication. In this study, we discuss the management of two cases of TAPS with different conditions. Case presentation: ...

Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Reports Q4 revenue $170.6M vs. $60M last year. “Protagonist is quickly approaching multiple late-stage transformational events expected in the ...

Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.